 |
|
|
| |
Nivolumab in Patients With Advanced Hepatocellular
Carcinoma: the CheckMate 040 Study
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Bruno Sangro,1Ignacio Melero,1Thomas Yau,2ChiunHsu,3Masatoshi Kudo,4Todd S. Crocenzi,5Tae-You Kim,6Su-Pin Choo,7JorgTrojan,8Tim Meyer,9Theodore H. Welling, III,10Winnie Yeo,11Akhil Chopra,12Jeffrey Anderson,13Christine
delaCruz,13LixinLang,13Jaclyn Neely,13HaoTang,13Anthony B. El-Khoueiry141Clinica Universidad de Navarra and CIBERehd, Pamplona, Spain; 2University of Hong Kong, Hong Kong, China; 3National Taiwan University Hospital, Taipei, Taiwan; 4Kindai University Faculty of Medicine, Osaka, Japan; 5Providence Cancer Center, Portland, OR, USA; 6Seoul National University Hospital, Seoul, Korea; 7National Cancer Center, Singapore; 8Goethe University Hospital and Cancer Center, Frankfurt, Germany; 9Royal Free Hospital, London, UK; 10University of Michigan School of Medicine, Ann Arbor, MI, USA; 11Chinese University of Hong Kong, Hong Kong, China; 12Johns Hopkins Singapore International Medical Centre, Singapore; 13Bristol-Myers Squibb, Princeton, NJ, USA;14USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA
|
| |
|
|
|
|
|
